Dr. Jiong Wu 吴炅
Oncology
Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public sources. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionCurrent positions
- Executive Vice President, Fudan University Shanghai Cancer Center
Checked against a public report (2025-06). Positions change; the hospital's website is the final word.
Clinical focus: Comprehensive diagnosis and treatment of breast cancer, including breast-conserving surgery, sentinel lymph node biopsy, immediate and delayed breast reconstruction, multidisciplinary care for locally advanced breast cancer, and counseling for hereditary breast cancer.
Conditions and procedures: Breast cancer, Locally advanced breast cancer, Hereditary breast cancer, Breast-conserving surgery, Sentinel lymph node biopsy, Breast reconstruction
Compiled from public information; not confirmed with the hospital or the doctor.
Name order: in Chinese the family name comes first (Wu Jiong). Papers usually list the name as Jiong Wu.
Selected publications
71 first- or senior-author papers on PubMed where the author's own affiliation is this hospital (63 since 2016). Most recent:
- Lancet Oncol, 2026 (senior author): Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial. PubMed 42987884
- Cancer Lett, 2026 (senior author): Event-free survival in patients with early triple-negative breast cancer receiving platinum-free, de-escalated anti-PD-1 neoadjuvant therapy: an updated analysis of the NeoTENNIS trial. PubMed 42982408
- Cancer Cell Int, 2026 (senior author): Retraction Note: Cyclin D3 predicts disease-free survival in breast cancer. PubMed 42839293
- Chin J Cancer Res, 2026 (senior author): Decoding age-stratified clinical and molecular heterogeneity in male breast cancer through multiomic profiling. PubMed 42712807
- Cell Death Dis, 2026 (senior author): Restoring the CD226 in CD8+T cells overcomes TIGIT-refractory immunity in HER2+ breast cancer. PubMed 42443153
- Plast Reconstr Surg Glob Open, 2026 (senior author): Shifting Practice Patterns in Implant-based Breast Reconstruction in China: Insights From a 13-year Large-scale Retrospective Cohort. PubMed 41983163
- Aesthetic Plast Surg, 2026 (senior author): Current Trends in Revision Surgery After Breast Reconstruction in China: Insights from a Nationwide Cross-Sectional Survey. PubMed 41350467
- iScience, 2026 (senior author): MSMO1 promotes chemotherapy resistance through modulation of T-MAS metabolism via PERK/elF2α/ATF4/CHOP pathway. PubMed 41782822
Each paper was checked automatically: the author listed with this name must give this hospital as their affiliation; because this name is common, the affiliation must also name the specialty. See the full PubMed search.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and recommend a treatment plan.
Get a specialist opinion